These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29845775)

  • 21. Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma.
    Rizk NP; Servais EL; Tang LH; Sima CS; Gerdes H; Fleisher M; Rusch VW; Adusumilli PS
    Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):482-6. PubMed ID: 22237988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MMP-1 is a (pre-)invasive factor in Barrett-associated esophageal adenocarcinomas and is associated with positive lymph node status.
    Grimm M; Lazariotou M; Kircher S; Stuermer L; Reiber C; Höfelmayr A; Gattenlöhner S; Otto C; Germer CT; von Rahden BH
    J Transl Med; 2010 Oct; 8():99. PubMed ID: 20946664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma.
    Hao Y; Triadafilopoulos G; Sahbaie P; Young HS; Omary MB; Lowe AW
    Gastroenterology; 2006 Sep; 131(3):925-33. PubMed ID: 16952561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma.
    Salmela MT; Karjalainen-Lindsberg ML; Puolakkainen P; Saarialho-Kere U
    Br J Cancer; 2001 Aug; 85(3):383-92. PubMed ID: 11487270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune microenvironment in Barrett's esophagus adjacent to esophageal adenocarcinoma: possible influence of adjacent mucosa on cancer development and progression.
    Gokon Y; Fujishima F; Taniyama Y; Ishida H; Yamagata T; Sawai T; Uzuki M; Ichikawa H; Itakura Y; Takahashi K; Yajima N; Hagiwara M; Nishida A; Ozawa Y; Sakuma T; Kanba R; Sakamoto K; Zuguchi M; Saito M; Kamei T; Sasano H
    Virchows Arch; 2020 Dec; 477(6):825-834. PubMed ID: 32533341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma.
    Realdon S; Dassie E; Fassan M; Dall'Olmo L; Hatem G; Buda A; Arcidiacono D; Diamantis G; Zhang H; Greene MI; Sturniolo GC; Rugge M; Alberti A; Battaglia G
    Dis Esophagus; 2015; 28(4):394-403. PubMed ID: 24708360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activin a signaling regulates cell invasion and proliferation in esophageal adenocarcinoma.
    Taylor C; Loomans HA; Le Bras GF; Koumangoye RB; Romero-Morales AI; Quast LL; Zaika AI; El-Rifai W; Andl T; Andl CD
    Oncotarget; 2015 Oct; 6(33):34228-44. PubMed ID: 26447543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucocorticoid-induced TNFR family-related receptor (GITR)-expression in tumor infiltrating leucocytes (TILs) is associated with the pathogenesis of esophageal adenocarcinomas with and without Barrett's mucosa.
    von Rahden BH; Kircher S; Kafka M; Stuermer L; Reiber C; Gattenlöhner S; Germer CT; Grimm M
    Cancer Biomark; 2010; 7(6):285-94. PubMed ID: 21694467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Systematic Review of Esophageal MicroRNA Markers for Diagnosis and Monitoring of Barrett's Esophagus.
    Mallick R; Patnaik SK; Wani S; Bansal A
    Dig Dis Sci; 2016 Apr; 61(4):1039-50. PubMed ID: 26572780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma.
    Dvorak K; Watts GS; Ramsey L; Holubec H; Payne CM; Bernstein C; Jenkins GJ; Sampliner RE; Prasad A; Garewal HS; Bernstein H
    Am J Gastroenterol; 2009 Feb; 104(2):302-9. PubMed ID: 19174784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toll-like Receptor 2 Signalling and the Lysosomal Machinery in Barrett's Esophagus.
    Verbeek RE; Siersema PD; Vleggaar FP; Ten Kate FJ; Posthuma G; Souza RF; de Haan J; van Baal JW
    J Gastrointestin Liver Dis; 2016 Sep; 25(3):273-82. PubMed ID: 27689189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro.
    De Gottardi A; Dumonceau JM; Bruttin F; Vonlaufen A; Morard I; Spahr L; Rubbia-Brandt L; Frossard JL; Dinjens WN; Rabinovitch PS; Hadengue A
    Mol Cancer; 2006 Oct; 5():48. PubMed ID: 17054793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma.
    Nancarrow DJ; Clouston AD; Smithers BM; Gotley DC; Drew PA; Watson DI; Tyagi S; Hayward NK; Whiteman DC; ;
    PLoS One; 2011; 6(7):e22513. PubMed ID: 21829465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid droplet biogenesis and COX-2 pathway activation are triggered by Barrett's esophagus and adenocarcinoma, but not esophageal squamous cell carcinoma risk factors.
    Carrossini N; Meireles Da Costa N; Andrade-Barreto E; Sousa VPL; Nicolau-Neto P; Souza-Santos PT; Mansur GR; Wernersbach L; Bozza PT; Viola JPB; Ribeiro Pinto LF
    Sci Rep; 2021 Jan; 11(1):981. PubMed ID: 33441691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered expression of CD44 and DKK1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.
    Darlavoix T; Seelentag W; Yan P; Bachmann A; Bosman FT
    Virchows Arch; 2009 Jun; 454(6):629-37. PubMed ID: 19396460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Origin of adenocarcinoma in Barrett's esophagus: p53 and Ki67 expression and histopathologic background.
    Szachnowicz S; Cecconello I; Iriya K; Marson AG; Takeda FR; Gama-Rodrigues JJ
    Clinics (Sao Paulo); 2005 Apr; 60(2):103-12. PubMed ID: 15880245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DCLK1 is detectable in plasma of patients with Barrett's esophagus and esophageal adenocarcinoma.
    Whorton J; Sureban SM; May R; Qu D; Lightfoot SA; Madhoun M; Johnson M; Tierney WM; Maple JT; Vega KJ; Houchen CW
    Dig Dis Sci; 2015 Feb; 60(2):509-13. PubMed ID: 25283374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nitric oxide-mediated invasion in Barrett's high-grade dysplasia and adenocarcinoma.
    Clemons NJ; Shannon NB; Abeyratne LR; Walker CE; Saadi A; O'Donovan ML; Lao-Sirieix PP; Fitzgerald RC
    Carcinogenesis; 2010 Sep; 31(9):1669-75. PubMed ID: 20584750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FABP1 and Hepar expression levels in Barrett's esophagus and associated neoplasia in an Asian population.
    Srivastava S; Kern F; Sharma N; McKeon F; Xian W; Yeoh KG; Ho KY; Teh M
    Dig Liver Dis; 2017 Oct; 49(10):1104-1109. PubMed ID: 28807490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abundant expression of the intestinal protein villin in Barrett's metaplasia and esophageal adenocarcinomas.
    Regalado SP; Nambu Y; Iannettoni MD; Orringer MB; Beer DG
    Mol Carcinog; 1998 Jul; 22(3):182-9. PubMed ID: 9688144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.